Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Assistance Publique - Hôpitaux de Paris
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
University of California, San Francisco
Institute of Hematology & Blood Diseases Hospital, China
Fondazione Italiana Linfomi - ETS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Charite University, Berlin, Germany
ImmunityBio, Inc.
Assistance Publique - Hôpitaux de Paris
Rigshospitalet, Denmark
City of Hope Medical Center
Fondazione Italiana Linfomi - ETS
University of Miami
Fondazione Italiana Linfomi - ETS
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
The Royal Wolverhampton Hospitals NHS Trust
M.D. Anderson Cancer Center
Beijing Tongren Hospital
Fred Hutchinson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Dizal Pharmaceuticals
University of Pennsylvania
University of Wisconsin, Madison
ASL Lecce
Fondazione Italiana Linfomi - ETS
University of Chicago
Eli Lilly and Company
Baylor College of Medicine
Amgen
Baylor College of Medicine
Rennes University Hospital
Baptist Health South Florida
PETHEMA Foundation
TORL Biotherapeutics, LLC
Cancer Research UK
M.D. Anderson Cancer Center
Novartis
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Novartis
Ascentage Pharma Group Inc.
St. Jude Children's Research Hospital
International Food Policy Research Institute
Mayo Clinic
Instituto Distrital de Ciencia, BiotecnologÃa e Innovación en Salud - IDCBIS